Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.

Cancer - 1 Mar 2013

Ohnstad Hege O, Castro Russell, Sun Jinchang, Heintz Karen-Marie, Vassilev Lyubomir T, Bjerkehagen Bodil, Kresse Stine H, Meza-Zepeda Leonardo A, Myklebost Ola

Abstract excerpt

BACKGROUND: Relatively few sarcomas harbor TP53 (tumor protein p53) mutations, but in many cases, amplification of MDM2 (murine double minute 2) effectively inactivate p53. The p53 pathway activity can also be affected by normal genetic variation. METHODS: The mutation status of TP53 and expression of MDM2, TP53, and their genetic variants SNP309 and R72P (Arg72Pro) were investigated in 125 sarcoma patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Imidazoles

Share to Piperazines

Share to Proto-Oncogene Proteins c-mdm2

Share to Sarcoma

Share to Treatment Outcome

Source

Identifiers

PMID: 23165797
DOI: 10.1002/cncr.27837

Genes

MDM2
MDM4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.PMID 23165797Read ↗

The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis.Semantic proximity Read ↗

TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.Semantic proximity Read ↗

Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis.Semantic proximity Read ↗

Ewing Sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs.Semantic proximity Read ↗

The Role of MDM2 Amplification and Overexpression in Tumorigenesis.Semantic proximity Read ↗

MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.Semantic proximity Read ↗

Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas.Semantic proximity Read ↗

Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.Semantic proximity Read ↗

Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.Semantic proximity Read ↗

TP53 mutational status is predictive of pazopanib response in advanced sarcomas.Semantic proximity Read ↗

Impact of MDM2 gene polymorphism on sarcoma risk.Semantic proximity Read ↗

p53 as a Potential Actionable Target in Myxofibrosarcoma: A Molecular and Pathologic Review of a Single-Institute Series.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.